SWOG clinical trial number
SWOG-9407

Evaluation of Oral Estramustine and Oral Etoposide in Patients with Hormone Refractory Adenocarcinoma of the Prostate, Phase II

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Advanced Prostate
Activated
03/01/1996
Closed
07/01/1996

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

2009

Cooperative group trials - Southwest Oncology Group (SWOG) innovations in advanced prostate cancer [PMID21085622; PMC2981166]

TB Dorff;C Tangen;ED Crawford;DP Petrylak;CS Higano;D Raghavan;DI Quinn;NJ Vogelzang;IM Thompson;MHA Hussain Therapeutic Advances in Medical Oncology 1(2):69-77;

2001

A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: a Southwest Oncology Group trial (SWOG-9407)

KJ Pienta;EI Fisher;MA Eisenberger;GM Mills;JW Goodwin;JA Jones;SR Dakhil;ED Crawford;MHA Hussain The Prostate 46:257-261

Other Clinical Trials

SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA8185

Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase